Compare IDT & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | AZTA |
|---|---|---|
| Founded | 1990 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Industrial Machinery/Components |
| Sector | Telecommunications | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1996 | 1995 |
| Metric | IDT | AZTA |
|---|---|---|
| Price | $49.92 | $35.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.60 |
| AVG Volume (30 Days) | 137.1K | ★ 631.1K |
| Earning Date | 12-04-2025 | 11-21-2025 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 18.50 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $1,231,495,000.00 | $593,821,000.00 |
| Revenue This Year | $0.77 | $6.13 |
| Revenue Next Year | N/A | $5.02 |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $44.77 | $23.91 |
| 52 Week High | $71.12 | $55.64 |
| Indicator | IDT | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 59.68 |
| Support Level | $48.96 | $34.34 |
| Resistance Level | $50.54 | $38.20 |
| Average True Range (ATR) | 1.21 | 1.47 |
| MACD | 0.11 | 0.31 |
| Stochastic Oscillator | 48.35 | 66.33 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.